Nexus Global Research Journal of Pharmaceutical Sciences
Journal Homepage: https://nexusglobalresearch.com/journals/ngrjps/

Review Article

Artificial Intelligence in Pharmaceutical Manufacturing and Quality Assurance: Applications, Opportunities, Challenges, and Future Perspectives

Ankita Roy [1*]

[1]*Bachelor of Pharmacy, Muzaffarpur College of Professional Education, Muzaffarpur Aryabhata Knowledge University, Bihar, India*

ABSTRACT:
Artificial intelligence (AI) is increasingly influencing pharmaceutical manufacturing and quality management by enabling data-driven process monitoring, prediction, automation, and decision support. This narrative review examines the application of AI across major pharmaceutical manufacturing operations and within quality assurance (QA) and quality control (QC). The review focuses on machine learning, deep learning, computer vision, natural language processing, predictive analytics, Internet of Things (IoT)-enabled monitoring, robotics, and digital-twin technologies. Potential applications include raw-material inspection, dispensing and weighing, granulation, blending, tablet compression, capsule filling, coating, packaging, warehouse management, predictive maintenance, documentation review, deviation management, corrective and preventive action (CAPA), validation support, risk assessment, visual inspection, laboratory-data interpretation, stability studies, and process analytical technology (PAT). AI can improve speed, consistency, traceability, and early detection of process or quality problems; however, these benefits depend on data quality, appropriate validation, cybersecurity, system integration, human oversight, and regulatory acceptability. Current regulatory activity, including the U.S. Food and Drug Administration's discussion paper on AI in drug manufacturing, demonstrates the growing importance of risk-based approaches to AI adoption. Overall, AI should be viewed as an enabling technology that augments, rather than replaces, pharmaceutical professionals. Responsible implementation combining validated digital systems with human expertise may support safer, more efficient, and more reliable pharmaceutical manufacturing.
Keywords: Artificial intelligence; pharmaceutical manufacturing; quality assurance; quality control; machine learning; computer vision; predictive analytics; Industry 4.0; process analytical technology; digital twins.

Citation: Roy A. (2026). Artificial Intelligence in Pharmaceutical Manufacturing and Quality Assurance: Applications, Opportunities, Challenges, and Future Perspectives. *Nexus Global Research Journal of Pharmaceutical Sciences, 1*(8), 400–406. **DOI:** https://doi.org/10.5281/zenodo.23430591

1. INTRODUCTION

Pharmaceutical manufacturing is a highly regulated activity in which the quality, safety, and efficacy of medicines depend on controlled materials, processes, equipment, personnel, documentation, and testing. Good Manufacturing Practice (GMP) requires pharmaceutical products to be consistently produced and controlled according to appropriate quality standards, with risks such as contamination, mix-ups, and inadequate process control appropriately managed [1]. Quality assurance provides the broader framework for preventing quality failures, while quality control verifies compliance through sampling, testing, and inspection.

The rapid development of digital technologies is changing how manufacturing data are collected and interpreted. Artificial intelligence refers to computational methods that perform tasks associated with functions such as pattern recognition, prediction, classification, and decision support. Machine learning (ML), a major component of AI, can identify relationships in historical and real-time data and generate predictions or classifications. Deep learning (DL) uses multilayer neural networks and is particularly useful for complex pattern recognition, including image analysis. Other enabling technologies include computer vision, natural language processing (NLP), IoT sensors, robotics, cloud computing, and digital twins.

***Corresponding Author:** Ankita Roy Email: ankitarayslg@gmail.com
Received: 20 Sept 2026 | **Accepted:** 10 Oct 2026 | **Published:** 17 Oct 2026
Copyright © 2026 The Author(s): This work is licensed under a Creative Commons Attribution- Non-Commercial-No Derivatives 4.0 (CC BY-NC-ND 4.0) International License

In pharmaceutical manufacturing, these technologies can be connected to equipment and quality systems to support real-time monitoring, predictive maintenance, process optimization, automated inspection, and data analysis. Industry 4.0 approaches have been discussed as an important pathway toward more connected and adaptive pharmaceutical manufacturing systems [2]. At the same time, AI introduces new questions concerning data integrity, model performance, explainability, cybersecurity, validation, change control, and regulatory oversight.

2. REVIEW APPROACH

This article was developed as a narrative literature review based on the material contained in the original project and an editorial correction of its structure, terminology, and references. The original project identified PubMed, Google Scholar, ScienceDirect, SpringerLink, WHO publications, U.S. FDA materials, ICH guidelines, peer-reviewed journals, and standard textbooks as information sources. The literature emphasis was on developments relevant to AI, pharmaceutical manufacturing, QA, QC, and Industry 4.0, with particular attention to recent literature.

Because this is a narrative review rather than a systematic review or meta-analysis, no quantitative pooled effect estimate is presented. The purpose is to synthesize major applications, benefits, limitations, and future directions rather than to claim that every published study has been identified.

3. APPLICATIONS OF AI IN PHARMACEUTICAL MANUFACTURING

3.1 Raw-Material Inspection

The quality of starting materials directly influences the quality of the finished product. AI-assisted inspection can combine imaging, sensor information, and classification algorithms to support identification of visual defects, contamination-related abnormalities, and material discrepancies. When appropriately validated, automated inspection can reduce repetitive manual work and provide consistent screening. However, the model should be trained and evaluated using representative, high-quality data and should operate within established material-release procedures.

3.2 Dispensing and Weighing

Dispensing requires accurate identification and measurement of active pharmaceutical ingredients and excipients against an approved formulation and batch record. Digital weighing systems can be integrated with barcode or electronic identification and verification systems. AI or rule-based automation may support anomaly detection, material traceability, inventory reconciliation, and error prevention. Final control should remain subject to approved procedures and authorized personnel.

3.3 Granulation

Granulation affects powder flow, compressibility, and downstream tablet performance. AI models can analyze process variables such as moisture, temperature, mixing conditions, and particle characteristics to support end-point prediction and process optimization. Such models may help identify trends before conventional end-point tests indicate a problem, particularly when combined with process analytical technology.

3.4 Blending

Blend uniformity is critical to dose consistency. Data-driven models can use sensor and process information to estimate blend behavior and support optimization of mixing time and operating conditions. The value of AI in this area is greatest when predictions are linked to validated process knowledge and appropriate sampling and testing strategies.

3.5 Tablet Compression

During compression, parameters such as compression force, tablet weight, thickness, hardness, machine speed, vibration, and tooling condition can be monitored. AI-based anomaly detection and predictive models may identify process drift or equipment problems earlier than periodic manual review. This can support more stable operation and reduce avoidable rejects, provided that model outputs are verified and integrated into the pharmaceutical quality system.

3.6 Capsule Filling

Capsule-filling systems require consistent dosing and reliable equipment operation. Computer vision and machine-learning approaches can assist with

capsule orientation, visible defects, fill-weight monitoring, and equipment-performance monitoring. Automated inspection can increase throughput while reducing operator fatigue, but critical quality decisions should remain controlled by validated procedures.

3.7 Tablet Coating

Coating affects appearance, protection of the tablet core, stability, and, depending on formulation, drug-release behavior. AI can be used to model relationships among spray rate, inlet and exhaust temperatures, pan speed, airflow, and coating performance. The objective is to maintain a stable process and reduce coating defects rather than to replace established process controls.

3.8 Packaging and Serialization

Packaging systems must protect products and provide accurate identification and traceability. Computer vision can support label verification, barcode and code reading, blister inspection, and detection of visible packaging defects. Automated inspection can improve consistency and help reduce errors, while serialization and electronic traceability can strengthen product tracking through the supply chain.

3.9 Warehouse and Supply-Chain Management

AI-supported forecasting can assist inventory planning, demand estimation, expiry monitoring, and storage management. When connected to appropriate sensors, digital systems can also monitor environmental conditions such as temperature and humidity. These applications may reduce wastage and improve stock availability, but forecasts remain dependent on the quality and representativeness of historical data.

3.10 Predictive Maintenance

Predictive maintenance is one of the most practical industrial applications of AI. Sensors can collect information about vibration, temperature, pressure, motor performance, and other equipment variables. ML models can identify patterns associated with equipment deterioration and estimate the likelihood of failure. Compared with purely calendar-based maintenance, predictive approaches may reduce unplanned downtime and help maintenance teams prioritize interventions.

4. AI IN QUALITY ASSURANCE AND QUALITY CONTROL

AI has potential value not only on the production floor but also across pharmaceutical quality systems. QA is primarily concerned with preventing failures through controlled systems, procedures, validation, documentation, training, audits, and continual improvement, whereas QC uses testing and inspection to determine whether materials and products meet established specifications. AI can support both functions, but its outputs must be appropriately governed and should not bypass established release, investigation, or change-control responsibilities.

4.1 Documentation and Data Review

Pharmaceutical operations generate large volumes of SOPs, batch manufacturing records, batch packaging records, equipment logs, validation documents, cleaning records, training records, deviations, and change-control records. NLP and document-analysis tools can assist with classification, retrieval, consistency checks, and identification of missing or anomalous information. These systems can reduce repetitive review, but automated outputs should be traceable and subject to human verification where they affect quality decisions.

4.2 Batch-Record Review

Electronic batch records can be screened for missing entries, inconsistent values, unusual patterns, and potential deviations. AI-assisted review may shorten the time required to identify records that need human attention. The technology should be treated as decision support rather than an independent authorization mechanism for batch release.

4.3 Deviation Management and CAPA

Historical deviation data can be analyzed to identify recurring event types, process areas, or contributing factors. AI may support classification, trend detection, risk prioritization, and investigation planning. For CAPA, AI can help identify recurring problems and monitor whether corrective or preventive actions are associated with improved outcomes. Root-cause conclusions, however, require appropriate scientific and quality-system judgment.

4.4 Validation and Risk Management

AI can assist in statistical analysis, trend monitoring, and risk prioritization. However, the use of AI itself creates validation requirements. The intended use, data sources, model performance, acceptance criteria, change management, and ongoing monitoring should be defined according to the risk associated with the application. ICH Q9(R1) emphasizes science- and risk-based quality risk management, which provides a useful framework for considering AI-related risks [3].

4.5 Audit and Inspection Readiness

Digital systems can search large document sets and identify missing records, overdue actions, or inconsistent information before an internal or regulatory inspection. Such tools may improve inspection readiness, but organizations should avoid treating AI-generated outputs as evidence of compliance without appropriate human review and verification.

4.6 Computer-Vision Inspection

Computer vision is particularly suited to high-volume visual inspection. Applications include identification of tablet or capsule defects, coating abnormalities, color variation, broken units, and packaging defects. The main advantage is consistent and rapid image-based screening. Performance should be demonstrated using representative images and predefined acceptance criteria, including appropriate handling of false positives and false negatives.

4.7 Laboratory Data Analysis

AI can support interpretation of data generated by analytical instruments such as HPLC, UV-visible spectroscopy, FTIR, gas chromatography, and dissolution testing. Potential uses include anomaly detection, trend recognition, and predictive modeling. AI should complement—not replace—validated analytical methods, instrument controls, specifications, and laboratory procedures.

4.8 Stability Studies and Shelf-Life Prediction

Stability programs generate time-dependent data under controlled environmental conditions. Statistical and machine-learning approaches may help identify degradation patterns and support exploratory shelf-life modeling. Any AI-derived prediction used for regulatory or product decisions requires appropriate scientific justification, validation, and alignment with applicable stability guidance.

4.9 Process Analytical Technology

Process Analytical Technology (PAT) emphasizes understanding and controlling manufacturing through timely measurement of critical process and quality information. AI can enhance PAT by combining multiple sensor streams, identifying complex relationships, and detecting emerging process deviations. This can support continuous process verification and more responsive manufacturing control when the models and measurement systems are appropriately qualified and validated.

5. KEY AI AND DIGITAL TECHNOLOGIES

Machine Learning

ML models learn statistical relationships from data and can be applied to predictive maintenance, process optimization, quality-risk assessment, demand forecasting, and anomaly detection.

Deep Learning

DL uses multilayer neural networks and is especially useful for complex pattern-recognition tasks such as image classification and automated visual inspection.

Computer Vision

Computer vision converts images or video into measurable information and can support inspection of tablets, capsules, labels, blister packs, and other manufacturing outputs.

Natural Language Processing

NLP can process large volumes of text and may assist with SOP review, batch-document analysis, regulatory-document search, literature screening, and pharmacovigilance workflows.

Predictive Analytics

Predictive analytics uses historical and current data to estimate future outcomes, including equipment failure, process performance, demand, or quality-related events.

Digital Twins

A digital twin is a digital representation of a physical process, equipment item, or system that can be updated using operational data. In manufacturing, digital twins can support simulation, process understanding, optimization, and maintenance planning.

IoT, Robotics, and Connected Systems

Sensors, industrial networks, robotics, and cloud or edge computing provide the data and infrastructure required for many AI-enabled manufacturing applications. Their integration is a central feature of Industry 4.0.

6. HUMAN INTELLIGENCE AND ARTIFICIAL INTELLIGENCE: A COMPLEMENTARY MODEL

The original project compared human intelligence and AI across decision-making, learning, speed, accuracy, working capacity, documentation, inspection, error detection, maintenance, cost, adaptability, creativity, and ethical decision-making. For a publication-oriented article, the key conclusion is better expressed as a complementary model rather than a simple competition between humans and machines.

Area	Human expertise	AI-enabled systems
Judgment	Context, experience, ethics, and professional responsibility	Pattern-based recommendations and predictions
Data processing	Strong contextual interpretation but limited by time and workload	Rapid analysis of large datasets
Repetitive inspection	Effective but affected by fatigue and variability	Consistent automated screening when validated
Unexpected situations	Flexible reasoning and adaptation	Performance depends on training data and defined use
Quality decisions	Accountability and final professional judgment	Decision support, alerts, and prioritization
Continuous monitoring	Limited by staffing and working hours	Can monitor systems continuously

This model is consistent with the principle that AI should augment professional expertise. Human personnel remain responsible for interpreting regulations, assessing context, investigating complex deviations, approving quality decisions, and ensuring that patient safety remains the primary objective.

7. POTENTIAL BENEFITS

- More efficient use of manufacturing and quality data.
- Earlier detection of process drift, equipment deterioration, and potential quality problems.
- Improved consistency in repetitive inspection and monitoring tasks.
- Reduced manual workload for selected documentation and data-review activities.
- Improved traceability and data visibility when digital systems are properly integrated.
- Support for predictive maintenance and reduced unplanned downtime.
- Better process understanding through integration of multiple data sources.
- Potential reductions in material wastage, rework, and avoidable production losses.
- Enhanced support for risk-based decision-making and continual improvement.

8. CHALLENGES AND REGULATORY CONSIDERATIONS

The implementation of AI in pharmaceutical manufacturing is not simply a software-installation exercise. Pharmaceutical companies must demonstrate that AI-enabled processes remain controlled, reliable, secure, and fit for their intended use. The FDA published a 2023 discussion paper specifically addressing AI in drug manufacturing and has continued to develop regulatory thinking around advanced manufacturing technologies [4]. In addition, the FDA's 2025 draft guidance on AI used

to support regulatory decision-making proposes a risk-based credibility assessment framework for AI models used in a defined context of use [5].

- Data quality and representativeness: poor, incomplete, biased, or poorly labeled data can produce unreliable outputs.
- Model validation and performance monitoring: models require predefined acceptance criteria, testing, version control, and ongoing monitoring.
- Explain ability and transparency: users may need to understand why a model produced a particular output, especially for high-impact quality decisions.
- Cybersecurity and data integrity: connected manufacturing systems increase the importance of access control, audit trails, secure architecture, and data-integrity controls.
- Integration with legacy systems: existing manufacturing and quality systems may not readily support modern AI tools.
- Cost and infrastructure: implementation may require sensors, computing infrastructure, software, validation resources, and specialist personnel.
- Regulatory uncertainty: requirements for AI-enabled systems continue to evolve, making lifecycle governance particularly important.
- Human oversight: AI should not be allowed to make uncontrolled quality or patient-safety decisions without appropriate human responsibility and governance.

9. FUTURE PERSPECTIVES

AI is likely to become increasingly integrated with continuous manufacturing, PAT, robotics, advanced analytics, and digital-twin environments. The longer-term direction is toward connected manufacturing systems that can combine data from equipment, materials, laboratory testing, and quality systems to support faster and more informed decisions.

Important areas for future development include explainable AI, AI-enabled robotics, digital twins, cloud and edge computing, autonomous monitoring, and more sophisticated predictive quality models. However, greater automation should be accompanied by stronger governance. Future pharmaceutical professionals will need both domain knowledge and digital literacy, including the ability to understand model limitations, data quality, validation, and the appropriate role of human review.

10. CONCLUSION

Artificial intelligence is emerging as an important enabling technology for pharmaceutical manufacturing and quality management. Its applications extend from raw-material inspection and process monitoring to predictive maintenance, automated visual inspection, documentation analysis, deviation management, laboratory-data interpretation, and PAT. Machine learning, deep learning, computer vision, NLP, predictive analytics, IoT, robotics, and digital twins can improve the speed and consistency with which pharmaceutical data are processed and acted upon.

The benefits of AI should not, however, be interpreted as evidence that human expertise is no longer necessary. Pharmaceutical manufacturing operates within a safety-critical and highly regulated environment in which scientific judgment, ethical responsibility, quality-system knowledge, and regulatory accountability remain essential. Successful adoption therefore depends on a human-in-the-loop approach supported by validated systems, reliable data, cybersecurity, lifecycle monitoring, and risk-based governance.

In conclusion, AI has substantial potential to contribute to smarter, safer, and more efficient pharmaceutical manufacturing. Its greatest value will be realized when intelligent technologies are integrated responsibly into established pharmaceutical quality systems rather than used as substitutes for professional judgment.

REFERENCES

1. World Health Organization. WHO good manufacturing practices for pharmaceutical products: main principles.
2. WHO Technical Report Series No. 986, Annex 2. Geneva: World Health Organization; 2014.
3. Arden NS, Fisher AC, Tyner KM, Yu LX, Lee SL, Kopcha M. Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart

factories of the future. International Journal of Pharmaceutics. 2021;602:120554. doi:10.1016/j.ijpharm.2021.120554.

4. International Council for Harmonisation. ICH Q9(R1): Quality Risk Management. Geneva: ICH; 2023.
5. U.S. Food and Drug Administration. Artificial Intelligence in Drug Manufacturing. Discussion Paper. Center for Drug Evaluation and Research; 2023.
6. U.S. Food and Drug Administration. Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products. Draft Guidance for Industry and Other Interested Parties. January 2025.
7. International Council for Harmonisation. ICH Q10: Pharmaceutical Quality System. Geneva: ICH; 2008.
   U.S. Food and Drug Administration. PAT—A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. Guidance for Industry. 2004.
8. Mottaghi-Dastjerdi N, Soltany-Rezaee-Rad M. Advancements and Applications of Artificial Intelligence in Pharmaceutical Sciences: A Comprehensive Review. Iranian Journal of Pharmaceutical Research. 2024;23(1):e150510. doi:10.5812/ijpr-150510.
9. Kandhare PD, Kurlekar M, Deshpande T, et al. Artificial intelligence in pharmaceutical sciences: A comprehensive review. Medicine in Novel Technology and Devices. 2025;27:100375. doi:10.1016/j.medntd.2025.100375.
10. Goodfellow I, Bengio Y, Courville A. Deep Learning. Cambridge, MA: MIT Press; 2016.
11. Russell SJ, Norvig P. Artificial Intelligence: A Modern Approach. 4th ed. Pearson; 2021.
12. LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015;521(7553):436–444. doi:10.1038/nature14539.
13. Jordan MI, Mitchell TM. Machine learning: Trends, perspectives, and prospects. Science. 2015;349(6245):255–260. doi:10.1126/science.aaa8415.
14. Tao F, Zhang H, Liu A, Nee AYC. Digital twin in industry: State-of-the-art. IEEE Transactions on Industrial Informatics. 2019;15(4):2405–2415.
15. World Health Organization. Ethics and Governance of Artificial Intelligence for Health. Geneva: World Health Organization; 2021.